Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:ADMA NASDAQ:INDV NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$34.46-2.4%$40.06$16.50▼$48.45$3.29BN/A6,776 shs6,625 shsADMAADMA Biologics$14.72+0.2%$15.92$13.50▼$25.67$3.51B0.473.20 million shs2.46 million shsINDVIndivior$24.09-0.8%$23.84$7.62▼$25.49N/A0.71.58 million shs2.55 million shsVALNValneva$9.87-0.9%$10.11$3.62▼$12.25$855.84M1.8665,931 shs46,745 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-2.41%-1.74%-11.30%-10.05%+3,445,999,900.00%ADMAADMA Biologics+0.20%-1.54%-7.48%-14.42%-5.76%INDVIndivior-0.82%-1.83%+7.02%+42.12%+191.29%VALNValneva-0.90%-5.19%-3.05%+34.84%+69.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$34.46-2.4%$40.06$16.50▼$48.45$3.29BN/A6,776 shs6,625 shsADMAADMA Biologics$14.72+0.2%$15.92$13.50▼$25.67$3.51B0.473.20 million shs2.46 million shsINDVIndivior$24.09-0.8%$23.84$7.62▼$25.49N/A0.71.58 million shs2.55 million shsVALNValneva$9.87-0.9%$10.11$3.62▼$12.25$855.84M1.8665,931 shs46,745 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-2.41%-1.74%-11.30%-10.05%+3,445,999,900.00%ADMAADMA Biologics+0.20%-1.54%-7.48%-14.42%-5.76%INDVIndivior-0.82%-1.83%+7.02%+42.12%+191.29%VALNValneva-0.90%-5.19%-3.05%+34.84%+69.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AADMAADMA Biologics 3.25Buy$27.6787.95% UpsideINDVIndivior 2.88Moderate Buy$22.00-8.68% DownsideVALNValneva 2.50Moderate Buy$15.0051.98% UpsideCurrent Analyst Ratings BreakdownLatest VALN, ADMA, INDV, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/8/2025INDVIndiviorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025VALNValnevaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/3/2025INDVIndiviorZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/27/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Buy (B-)9/27/2025INDVIndiviorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025VALNValnevaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $13.008/27/2025INDVIndiviorCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $34.008/25/2025VALNValnevaJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$14.008/25/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.00(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M23.90N/AN/A$0.48 per share71.79ADMAADMA Biologics$474.17M7.41$0.54 per share27.14$1.48 per share9.95INDVIndivior$1.19BN/A$1.81 per share13.34($2.52) per shareN/AVALNValneva$183.52M4.62$0.10 per share101.93$2.41 per share4.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/AADMAADMA Biologics$197.67M$0.8617.1221.33N/A44.06%41.01%28.47%11/6/2025 (Estimated)INDVIndivior$2M$0.6238.8614.09N/A6.65%-86.28%16.26%10/30/2025 (Estimated)VALNValneva-$13.25M-$0.98N/AN/AN/A-33.87%-34.78%-13.43%11/6/2025 (Estimated)Latest VALN, ADMA, INDV, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ADMAADMA Biologics$0.16N/AN/AN/A$131.20 millionN/A10/30/2025Q3 2025INDVIndivior$0.38N/AN/AN/A$257.66 millionN/A8/12/2025Q2 2025VALNValneva-$0.27-$0.16+$0.11-$0.16$46.28 million$54.84 million8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 million7/31/2025Q2 2025INDVIndivior$0.26$0.51+$0.25$0.14$239.43 million$302.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International1.311.541.53ADMAADMA Biologics0.215.332.78INDVIndiviorN/A0.900.76VALNValneva0.662.271.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AADMAADMA Biologics75.68%INDVIndivior60.33%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AADMAADMA Biologics3.70%INDVIndiviorN/AVALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.17 millionN/AN/AADMAADMA Biologics530238.63 million229.80 millionOptionableINDVIndivior1,051N/AN/ANot OptionableVALNValneva70085.93 million73.12 millionNot OptionableVALN, ADMA, INDV, and AAPG HeadlinesRecent News About These CompaniesValneva SE Sponsored ADR (NASDAQ:VALN) Short Interest Update3 hours ago | marketbeat.comFDA Vaccine Suspensions: Outliers Or The New Normal?October 21 at 4:42 PM | healthaffairs.orgHValneva (NASDAQ:VALN) Stock Price Down 0.8% - What's Next?October 21 at 3:01 AM | americanbankingnews.comValneva (NASDAQ:VALN) Trading Down 0.8% - Time to Sell?October 21 at 2:58 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNOctober 18, 2025 | prnewswire.comOngoing Valneva SE (VALN) Investigation: Protect Your Rights - Contact Levi & KorsinskyOctober 16, 2025 | theglobeandmail.comNew York reports first locally acquired chikungunya case in U.S. since 2019October 16, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNOctober 13, 2025 | prnewswire.comValneva (NASDAQ:VALN) Stock Price Down 4.9% - Here's WhyOctober 11, 2025 | marketbeat.comWeiss Ratings Reaffirms Sell (D-) Rating for Valneva (NASDAQ:VALN)October 9, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNOctober 8, 2025 | prnewswire.comValneva stock falls after FDA suspension forces guidance cutOctober 7, 2025 | investing.comValneva's Critical Juncture: Lyme Disease Vaccine Holds Key to SurvivalOctober 7, 2025 | aktiencheck.deAValneva Shares Slide After FDA Suspension Prompts Guidance RevisionOctober 7, 2025 | msn.comValneva (NASDAQ:VALN) Shares Gap Down - What's Next?October 7, 2025 | marketbeat.comValneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business UpdatesOctober 6, 2025 | globenewswire.comVALNEVA Declaration of shares and voting rights: September 30, 2025October 6, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNOctober 3, 2025 | prnewswire.comValneva reports good antibody persistence for chikungunya vaccineOctober 1, 2025 | cidrap.umn.eduCLyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsightOctober 1, 2025 | finance.yahoo.comValneva’s Ixchiq shows 95% 4-year antibody persistence, shares up 10%September 30, 2025 | ca.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Why Vertical Aerospace Could Lead the eVTOL Market by 2028By Jeffrey Neal Johnson | September 30, 2025VALN, ADMA, INDV, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$34.46 -0.85 (-2.41%) As of 10/21/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.ADMA Biologics NASDAQ:ADMA$14.72 +0.03 (+0.20%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$14.86 +0.14 (+0.95%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Indivior NASDAQ:INDV$24.09 -0.20 (-0.82%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$24.08 -0.02 (-0.06%) As of 10/21/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Valneva NASDAQ:VALN$9.88 -0.08 (-0.84%) As of 10/21/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
